---
id: FC-311
type: Flashcard
created: 2025-08-08 10:01:38.443408
tags:
- Flashcard
- question
- cardiovascular
topic: cardiovascular
answer: B
related_articles:
- title: In Older Adults With Type 2 Diabetes, GLP-1 Receptor Agonists Decrease Major
    Adverse Cardiovascular Events; SGLT-2 Inhibitors Prevent Heart Failure Hospitalizations.
  path: 2025/2025-03-in-older-adults-with-type-2-diabetes-glp-1-receptor-agonists.md
  similarity: 0.727
  link: '[[2025/2025-03-in-older-adults-with-type-2-diabetes-glp-1-receptor-agonists|In
    Older Adults With Type 2 Diabetes, GLP-1 Receptor Agonists Decrease Major Adverse
    Cardiovascular Events; SGLT-2 Inhibitors Prevent Heart Failure Hospitalizations.]]'
- title: SGLT-2 Inhibitors Reduce Heart Failure-Related Hospitalization in Patients
    Without Diabetes.
  path: 2022/2022-10-sglt-2-inhibitors-reduce-heart-failure-related-hospitalizati.md
  similarity: 0.583
  link: '[[2022/2022-10-sglt-2-inhibitors-reduce-heart-failure-related-hospitalizati|SGLT-2
    Inhibitors Reduce Heart Failure-Related Hospitalization in Patients Without Diabetes.]]'
- title: DPP-4 Inhibitors, GLP-1 Receptor Agonists, and SGLT-2 Inhibitors for People
    With Cardiovascular Disease.
  path: 2022/2022-07-dpp-4-inhibitors-glp-1-receptor-agonists-and-sglt-2-inhibito.md
  similarity: 0.545
  link: '[[2022/2022-07-dpp-4-inhibitors-glp-1-receptor-agonists-and-sglt-2-inhibito|DPP-4
    Inhibitors, GLP-1 Receptor Agonists, and SGLT-2 Inhibitors for People With Cardiovascular
    Disease.]]'
- title: SGLT-2 Inhibitors Reduce Cardiovascular Mortality, but Benefit Is Modest,
    Even in Patients With Established Heart Disease.
  path: 2025/2025-01-sglt-2-inhibitors-reduce-cardiovascular-mortality-but-benefi.md
  similarity: 0.545
  link: '[[2025/2025-01-sglt-2-inhibitors-reduce-cardiovascular-mortality-but-benefi|SGLT-2
    Inhibitors Reduce Cardiovascular Mortality, but Benefit Is Modest, Even in Patients
    With Established Heart Disease.]]'
- title: PREVENT Equations for Assessing Cardiovascular Risk.
  path: 2024/2024-09-prevent-equations-for-assessing-cardiovascular-risk.md
  similarity: 0.545
  link: '[[2024/2024-09-prevent-equations-for-assessing-cardiovascular-risk|PREVENT
    Equations for Assessing Cardiovascular Risk.]]'
topics:
- Blood Pressure
- Cardiology
- Endocrinology
- Geriatrics
- Pharmacology
- Preventive Medicine
- Psychiatry
- Side Effects
related_articles_2023_2025:
- title: editorial cardiovascular disparities south asian people
  path: 2024/07/2024-07-editorial-cardiovascular-disparities-south-asian-people.md
  similarity: 0.307
  link: '[[2024/07/2024-07-editorial-cardiovascular-disparities-south-asian-people|editorial
    cardiovascular disparities south asian people]]'
last_updated: '2025-08-10T20:23:55.260227'
---

# Flashcard FC-311

## Question

A55-year-oldfemalecomestoyourclinicforfollow-upofherhypertensionthathasbeendifficultto control. Hermedicalhistoryalsoincludestype2 diabetesandobstructivesleepapnea(OSA). Her BMIis 52 kg/m2. Herheart rateis62 beats/minandregular. Herblood pressureintheclinictodayis160/96 mm Hg,andshereportssimilaraveragereadingsathome. Sheisasymptomaticandsaysshehasbeen followinglifestylemodificationsincludingalow-saltdiet. Shealsoreportsthatshehasbeenadherent withher CPAPtherapyandhercurrentantihypertensiveregimen,whichincludesthefollowing: Amlodipine(Norvasc),10 mgdaily Carvedilol(Coreg),25 mgtwicedaily Chlorthalidone,25 mgdaily Losartan(Cozaar),100 mgdaily which one of the followingantihypertensivemedicationchangeswould bethemostappropriatenext choiceformanagingherhypertension?

## Answer

**B**

## Explanation

Amineralocorticoidreceptorantagonistisrecommendedforpatientswhoseblood pressureisnot controlledonarenin/angiotensinblocker,adiuretic,andacalciumchannelblocker. Thispatientis additionallyona B-blocker. Spironolactoneisrecommendedfirst,titratedtoeithereffectivenessorside effects. Ifitisnottolerated,eplerenonecanalsobeused. Itisestimatedthatalmost17-22 ofpatientswithresistanthypertensionmayhaveundiagnosed primaryhyperaldosteronism. Evaluationforhyperaldosteronismwouldalsobeaconsiderationforthis patientduetothediagnosisofresistanthypertension,butthecurrentrecommendationfortreatmentof primaryhyperaldosteronismisspironolactone. a

## References

- AAFPQuestion Bank-Pythonsimplecapture.
- whoseblood pressureisnot

